ASTRAZENECA PLC（AZN）適時開示・決算発表
| 提出日 | 様式 | 項目 | 原文 |
|---|---|---|---|
| 2026-10-05 | 6-K | ASTRAZENECA COMPLETES EQUITY INVESTMENT IN SUMMIT | SEC |
| 2026-10-02 | 6-K | AZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY | SEC |
| 2026-10-01 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2026-10-01 | 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | SEC |
| 2026-09-29 | 6-K | ASTRAZENECA ANNOUNCES EQUITY INVESTMENT IN SUMMIT | SEC |
| 2026-09-23 | 6-K | TRIXEO APPROVED IN EU FOR ASTHMA | SEC |
| 2026-09-21 | 6-K | ENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC | SEC |
| 2026-09-21 | 6-K | KLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMP | SEC |
| 2026-09-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-09-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-09-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-09-14 | 6-K | UPDATE ON SERENA-4 PHASE III TRIAL | SEC |
| 2026-09-08 | 6-K | ETCAMAH APPROVED IN THE US FOR HR+ BREAST CANCER | SEC |
| 2026-09-08 | 6-K | IMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNG | SEC |
| 2026-09-01 | 6-K | TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG | SEC |
| 2026-09-01 | 6-K | ASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVY | SEC |
| 2026-09-01 | 6-K | DIRECTORATE CHANGE | SEC |
| 2026-09-01 | 6-K | ENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBC | SEC |
| 2026-09-01 | 6-K | ADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERING | SEC |
| 2026-09-01 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2026-09-01 | 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | SEC |
| 2026-08-27 | 6-K | TEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTS | SEC |
| 2026-08-25 | 6-K | ASTRAZENECA PRICES A EUR2.55 BILLION BOND OFFERING | SEC |
| 2026-08-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-08-17 | 6-K | TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG | SEC |
| 2026-08-17 | 6-K | UPDATE ON EVOLVE-LUNG02 PHASE III TRIAL | SEC |
| 2026-08-17 | 6-K | ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER | SEC |
| 2026-08-03 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2026-08-03 | 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | SEC |
| 2026-07-31 | 6-K | DATROWAY APPROVED IN EU FOR TNBC | SEC |
| 2026-07-27 | 6-K | FORM 6-K | SEC |
| 2026-07-27 | 6-K | SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS | SEC |
| 2026-07-27 | 6-K | UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA | SEC |
| 2026-07-23 | 6-K | ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER | SEC |
| 2026-07-14 | 6-K | ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR | SEC |
| 2026-07-09 | 6-K | UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL | SEC |
| 2026-07-01 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2026-07-01 | 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | SEC |
| 2026-06-29 | 6-K | DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC | SEC |
| 2026-06-29 | 6-K | ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS | SEC |
| 2026-06-15 | 6-K | TRUQAP APPROVED IN US FOR PROSTATE CANCER | SEC |
| 2026-06-01 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2026-06-01 | 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | SEC |
| 2026-05-29 | 6-K | IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER | SEC |
| 2026-05-27 | 6-K | US FDA DECISION DATE ON CAMIZESTRANT EXTENDED | SEC |
| 2026-05-26 | 6-K | CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU | SEC |
| 2026-05-26 | 6-K | ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS | SEC |
| 2026-05-26 | 6-K | DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC | SEC |
| 2026-05-18 | 6-K | ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS | SEC |
| 2026-05-18 | 6-K | BAXFENDY APPROVED IN THE US FOR HYPERTENSION | SEC |
| 2026-05-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-05-14 | 6-K | IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER | SEC |
| 2026-05-01 | 6-K | FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCER | SEC |
| 2026-05-01 | 6-K | FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER | SEC |
| 2026-05-01 | 6-K | TOTAL VOTING RIGHTS AND ADMISSION OF SHARES | SEC |
| 2026-04-29 | 6-K | 1ST QUARTER RESULTS | SEC |
| 2026-04-28 | 6-K | BREZTRI APPROVED IN THE US FOR ASTHMA | SEC |
| 2026-04-27 | 6-K | SAPHNELO SELF-ADMINISTRATION APPROVED IN THE US | SEC |
| 2026-04-23 | 6-K | DIRECTORATE CHANGE | SEC |
| 2026-04-21 | 6-K | I CAN PHIII INTERIM ANALYSIS MET PRIMARY ENDPOINT | SEC |
出典は SEC EDGAR の 8-K／6-K。8-K は米国内企業の臨時報告（Item 2.02 が決算発表）、6-K は外国企業（ADR 含む）の対応様式です。当サイトはリンクの整理のみ行い、原文はすべて sec.gov にあります。「動画」は会社のプレスリリースに記載された決算説明会 webcast の URL、「IR ページ」はプレスリリースが案内している会社の IR ページで、リプレイの公開期間は限られます。決算説明会の日時は同じプレスリリースの記載どおりで、米国現地時間（ET 東部・CT 中部・MT 山岳部・PT 太平洋）です。